AMAG CMO hits the exit just as biotech searches for new CEO to right a ship rocked by Makena controversy
Heading into 2020, AMAG Pharmaceuticals has sketched big plans to salvage its wobbly operations — battling a revenue squeeze and a critical FDA review of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
